2,855
edits
Psychedelic Therapy Inclusion and Exclusion Criteria: Difference between revisions
Psychedelic Therapy Inclusion and Exclusion Criteria (view source)
Revision as of 02:44, 15 July 2023
, 02:44, 15 July 2023no edit summary
(Created page with "Certain types of patient are more at risk of certain side effects to psychedelic medicine. Therefore, a judgement needs to be made pre-administration to recommend to the patient where it is safe to take the medicine or not. Below is a list of inclusion criteria (people who would be deemed less likely for adverse effects) and exclusion criteria (those that it should not be recommended to take psychedelics). == Inclusion Criteria == Participants meeting a...") |
mNo edit summary |
||
| Line 1: | Line 1: | ||
Certain types of patient are more at risk of | Certain types of patient are more at risk of adverse side effects to [[Psychedelics|psychedelic]] medicine. Therefore, a judgement needs to be made pre-administration to recommend to the patient where it is safe to take the medicine or not. Below is a list of inclusion criteria (people who would be deemed less likely for adverse effects) and exclusion criteria (those that it should not be recommended to take psychedelics) extracted from clinical data up to July 2023<ref>'''Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication.''' '''Goodwin, G.M., Croal, M., Feifel, D. ''et al.''''' ''Neuropsychopharmacol.'' (2023). Accessed 15 Jul 2023 via https://www.nature.com/articles/s41386-023-01648-7</ref>. | ||
== Inclusion Criteria == | == Inclusion Criteria == | ||
| Line 57: | Line 57: | ||
9. Any other clinically significant cardiovascular, pulmonary, gastrointestinal, hepatic, renal or any other major concurrent illness that, in the opinion of the investigator, may have interfered with the interpretation of the study results or constitute a health risk for the participant if he/she took part in the study. | 9. Any other clinically significant cardiovascular, pulmonary, gastrointestinal, hepatic, renal or any other major concurrent illness that, in the opinion of the investigator, may have interfered with the interpretation of the study results or constitute a health risk for the participant if he/she took part in the study. | ||
'''Reference''' | |||